RE:RE:RE:RE:RE:RE:RE:RE:Short selling could very well be the reason for 30% declineOutperformRX wrote: I asked IR why they are increasing Donnatol sales force so much and they haven't answered my question either. So I asked my doctor. She said Donnatal is being quickly displaced by H2 antagonists as in slinical rials it is showing more effectiveness and lack many of the advserse effects of phenobarbital. Pumpers, plese report to your laptops. Not sure if she is correct or not but there has to be a reason why they are pushing the Donnatal cocktail.
Your doctor needs to educate herself about the purpose of Donnatal, unless of course you misunderstood her.
It is actually the H2 blockers that are being replaced... not Donnatal.
Donnatal is a medication that treats IBS. It is an effective treatment of intestinal irritation, constipation, cramps, spastic colon, pain associated with various stomach, intestinal, and bowel disorders, including acute colitis.
It does not compete with H2 blockers that were once used to treat P. Ulcers or PPIs such as "Nexium", that reduces excess acid production to prevent acid reflux that can damage your esophagus.
Donnatal apparently provides unparalleled relief to IBS patients that no other drug is capable of. Patient testimonials back this up. Since it's purchase by CXR, Donnatal has doubled in sales. In addition, IBS is more prevalent today than at any time in the past. Donnatal has a great future and further potential for growth through name recognition. This is why the sales force is being increased by 100. It is an offensive move not a defensive one.
Please note;
"The H2 blockers (also called H2 antagonists) were the first effective drugs for peptic ulcer. In the 1980s, they were the mainstay of treatment for ulcers and gastroesophageal reflux disease (GERD).
Now, antibiotics cure non-NSAID ulcers, and proton pump inhibitors (PPIs) are better for GERD. Therefore, H2 antagonists face an uncertain future as prescription drugs."
Source https://iffgd.org/